[1]
Chen, Z.-S. and Yang, D.-H. 2021. Selection of optimal therapeutic modality for early-stage extranodal natural killer/T-cell lymphoma patients under the guidance of single-nucleotide polymorphism signature. Bosnian Journal of Basic Medical Sciences. (Aug. 2021). DOI:https://doi.org/10.17305/bjbms.2021.6419.